New combo therapy aims to tame deadly transplant complication
NCT ID NCT07184853
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether adding etanercept to the standard drug ruxolitinib can better control severe graft-versus-host disease (GVHD) in people who have had a stem cell transplant. GVHD occurs when donor immune cells attack the recipient's body, and current treatments often fail. About 122 participants will be randomly assigned to receive either ruxolitinib alone or ruxolitinib plus etanercept, with the main goal of seeing if the combination leads to a higher response rate after 28 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ruxolitinib and etanercept
What this could lead to
If successful, this combination could offer a more effective treatment option for patients with severe graft-versus-host disease that does not respond to steroids, potentially improving survival.
What could go wrong
This is a relatively small, early-stage trial (122 participants) and the combination may not prove superior to ruxolitinib alone. There are also risks of increased side effects from adding another immunosuppressant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT VS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••